ArticleNature neuroscience2020
AHR is a Zika virus host factor and a candidate target for antiviral therapy.
Article in Nature neuroscience, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 60 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 103 citations in OpenAlex.
- Mechanistic Insights into Regulation of the Aryl Hydrocarbon Receptor Expression in Mouse and Human Hepatoma Cells.International journal of molecular sciences · 2026Article
- Marine-Derived Natural Products Against Flaviviruses: Mechanisms, Evidence, and Future Directions.Marine drugs · 2026Review
- Commensal bacteria inhibit viral infections via a tryptophan metabolite.Nature communications · 2026Article
- SLC3A2 promotes early-stage of Zika virus infection in human placental cells and astrocytes.Infectious diseases & immunity · 2026Article
- Japanese encephalitis virus hijacks the host purine biosynthetic network to promote viral replication in neurons.PLoS pathogens · 2026Article
- Aryl hydrocarbon receptor pharmacology-mechanisms, ligands, and therapeutic potential.Pharmacological reviews · 2026Review
- Vitamin A Modulates AHR Signaling and Restricts Zika Virus Replication in Human Retinal Pigment Epithelial Cells: Insights from Molecular Modeling and Antiviral Assays.Pathogens (Basel, Switzerland) · 2026Article
- Potential Activity of 6-Pentyl-α-pyrone as an Antiviral for Bovine Coronavirus.Pathogens (Basel, Switzerland) · 2026Article
- Effect of the AHR Inhibitor CH223191 as an Adjunct Treatment for Mammarenavirus Infections.International journal of molecular sciences · 2026Article
- The aryl hydrocarbon receptor: structure, signaling, physiology and pathology.Signal transduction and targeted therapy · 2026Review
- The kynurenine pathway in RNA virus infection: immunometabolic control of antiviral defense and viral persistence.Frontiers in immunology · 2026Review
- Aryl hydrocarbon receptor restrains tonic cytokine responses by inhibiting microbiota sensing in monocytes.The Journal of clinical investigation · 2025Article
- Infectious Bronchitis Virus Activates the Aryl Hydrocarbon Receptor During In Vitro Infection.Veterinary sciences · 2025Article
- Novel and repurposed antiviral molecules for arbovirus infections with epidemic Potential: A systematic review.New microbes and new infections · 2025Review
- The aryl hydrocarbon receptor: a rehabilitated target for therapeutic immune modulation.Nature reviews. Drug discovery · 2025Review
- Using the Key Characteristics Framework to Unlock the Mysteries of Aryl Hydrocarbon Receptor-Mediated Effects on the Immune System.Annual review of immunology · 2025Review
- The role of the AHR in host-pathogen interactions.Nature reviews. Immunology · 2025Review
- Intestinal microbiome metabolites control sepsis outcome.Nature immunology · 2025Article
- The role of aryl hydrocarbon receptor signalling in COVID-19 pathology and its therapeutic potential.Frontiers in molecular medicine · 2025Review
- Construction and validation of a mouse model for studying severe human adenovirus infections.Virologica Sinica · 2024Article
Corrections and comments
- Erratum issued
Authors and funding
25 authors at 8 institutions in 3 countries.
Funding
Abstract
Zika virus (ZIKV) is a flavivirus linked to multiple birth defects including microcephaly, known as congenital ZIKV syndrome. The identification of host factors involved in ZIKV replication may guide efficacious therapeutic interventions. In genome-wide transcriptional studies, we found that ZIKV infection triggers aryl hydrocarbon receptor (AHR) activation. Specifically, ZIKV infection induces kynurenine (Kyn) production, which activates AHR, limiting the production of type I interferons (IFN-I) involved in antiviral immunity. Moreover, ZIKV-triggered AHR activation suppresses intrinsic immunity driven by the promyelocytic leukemia (PML) protein, which limits ZIKV replication. AHR inhibition suppressed the replication of multiple ZIKV strains in vitro and also suppressed replication of the related flavivirus dengue. Finally, AHR inhibition with a nanoparticle-delivered AHR antagonist or an inhibitor developed for human use limited ZIKV replication and ameliorated newborn microcephaly in a murine model. In summary, we identified AHR as a host factor for ZIKV replication and PML protein as a driver of anti-ZIKV intrinsic immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.